Skip to main content
European Commission logo print header

Feasibility of new breast cancer genes as tumour markers for prognosis and management of breast cancer patients


Novel breast cancer genes essential for the development of sporadic breast malignancies have been identified by differential display and subtractive cDNA cloning strategies. The gene products of DIT1A12, an insulin-like growth factor binding protein, and T2E5, a human membrane protein, will be evaluated for their feasibility as tumour markers in breast cancer patient serum and biopsies. An Elisa method for larger scale screening of serum samples and an insitu hybridisation technique to examine gene expression in tissue specimen will be developed. If the genes are useful markers, they can be exploited for breast cancer detection kits. This joint venture of Canadian and British-German research teams will apply advances in molecular oncology in a disease oriented manner to give, if successful, oncologists a tool for early detection and prognosis of breast malignancies and subsequent women diagnosed with breast cancer or breast cancer predisposition increased chances for effective treatment and survival.

Call for proposal

Data not available


University of Bradford
Richmond road
BD7 1DP West yorkshire - bradford
United Kingdom

See on map

EU contribution
No data

Participants (1)